{
  "id": 15087041,
  "title": "Opaleye management, 10% owner, buys $136,177 Grace Therapeutics (GRCE)",
  "url": "https://urgent.news/2026/10/17/opaleye-management-10-owner-buys-136-177-grace-therapeutics-grce",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T01:01:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/opaleye-management-10-owner-buys-136177-grace-therapeutics-grce-93CH-4955075"
  },
  "original_language": "en",
  "account": null,
  "summary": "Investing.com reports that Opaleye Management Inc., a 10% owner and director of Grace Therapeutics (GRCE), has increased its stake in the company by purchasing $136,177 worth of shares across multiple transactions between October 14 and October 16, 2026. The company traded at approximately $1.89, close to its 52-week low of $1.79, and analysts consider it undervalued with price targets ranging from $3.92 to $7.88. Opaleye Management acquired 11,233 shares on October 14 at an average price of $1.9349, followed by 23,485 shares on October 15 at $1.9453, and finally 36,347 shares on October 16 at $1.8917. After these purchases, the firm now owns a total of 2,944,354 shares of GRCE common stock.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}